Cytogen Inc
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained wit… Read more
Cytogen Inc - Asset Resilience Ratio
Cytogen Inc (217330) has an Asset Resilience Ratio of 39.93% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Cytogen Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Cytogen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩27.02 Billion | 39.93% |
| Total Liquid Assets | ₩27.02 Billion | 39.93% |
Asset Resilience Insights
- Very High Liquidity: Cytogen Inc maintains exceptional liquid asset reserves at 39.93% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cytogen Inc Industry Peers by Asset Resilience Ratio
Compare Cytogen Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Cytogen Inc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Cytogen Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 56.85% | ₩41.20 Billion | ₩72.48 Billion | -16.88pp |
| 2023-12-31 | 73.72% | ₩54.89 Billion | ₩74.45 Billion | +34.66pp |
| 2022-12-31 | 39.06% | ₩16.10 Billion | ₩41.22 Billion | -24.65pp |
| 2021-12-31 | 63.71% | ₩35.38 Billion | ₩55.53 Billion | +7.57pp |
| 2020-12-31 | 56.14% | ₩15.89 Billion | ₩28.31 Billion | -8.89pp |
| 2019-12-31 | 65.03% | ₩12.82 Billion | ₩19.72 Billion | +9.11pp |
| 2018-12-31 | 55.92% | ₩12.72 Billion | ₩22.75 Billion | -23.46pp |
| 2017-12-31 | 79.38% | ₩4.51 Billion | ₩5.68 Billion | +24.16pp |
| 2016-12-31 | 55.22% | ₩2.80 Billion | ₩5.06 Billion | -- |